Literature DB >> 5031683

Curative radiotherapy in Hodgkin's disease: significance of haematogenous dissemination established by examination of peripheral blood and spleen.

M R Halie, J J Seldenrath, H C Stam, H O Nieweg.   

Abstract

Studies of peripheral blood leucocyte concentrates in patients with Hodgkin's disease showed two types of cells believed to be typical for the disease in a number of patients. Involvement of the spleen as diagnosed after splenectomy and histological examination showed a close correlation with the presence of these characteristic cells in the peripheral blood. This is believed to be an argument for haematogenous spread or a multicentric origin of the disease in these cases. The results of attempted curative high-voltage radiotherapy with total node irradiation in 24 patients seem to support this concept. On the basis of the Rye classification of clinical stages the results of radiotherapy are not predictable. Six patients in stage II and seven in stage III were in remission, one in each of stages II and IV, and six in stage III had recurrences of the disease within one year. A division into localized or disseminated forms of the disease based on the investigations of blood and spleen showed all localized cases in remission; of the disseminated cases one reached a remission and all others had recurrences. In three patients the therapy could not be completed. These preliminary treatment results are believed to support the idea of a special role of the spleen in the dissemination of the disease. A new classification of clinical stages in Hodgkin's disease is proposed.

Entities:  

Mesh:

Year:  1972        PMID: 5031683      PMCID: PMC1788382          DOI: 10.1136/bmj.2.5814.611

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  The significance of the leucocyte concentrate in the demonstration of tumour cells in the blood.

Authors:  A M STOFBERG
Journal:  Acta Haematol       Date:  1963-02       Impact factor: 2.195

2.  Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas.

Authors:  H S Kaplan
Journal:  N Engl J Med       Date:  1968-04-18       Impact factor: 91.245

3.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

4.  Construction of auxiliary diaphragms for megavoltage irradiation of large, irregularly shaped fields.

Authors:  J G van Dorssen; J H Mellink; P Thomas
Journal:  Radiol Clin Biol       Date:  1970

5.  The pathology and nomenclature of Hodgkin's disease.

Authors:  R J Lukes; J J Butler
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

6.  Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials.

Authors:  H S Kaplan; S A Rosenberg
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

7.  Prophylactic treatment of adjacent areas in Hodgkin's disease.

Authors:  M V Peters
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

8.  Observations on abnormal cells in the peripheral blood and spleen in Hodgkin's disease.

Authors:  M R Halie; R Eibergen; H O Nieweg
Journal:  Br Med J       Date:  1972-06-10
  8 in total
  4 in total

Review 1.  [Diagnostic and therapeutic procedures in Hodgkin's disease].

Authors:  D Huhn; C Steidle
Journal:  Blut       Date:  1973-08

2.  Observations on abnormal cells in the peripheral blood and spleen in Hodgkin's disease.

Authors:  M R Halie; R Eibergen; H O Nieweg
Journal:  Br Med J       Date:  1972-06-10

3.  The results of radiotherapy for Hodgkins' disease.

Authors:  M J Peckham; H T Ford; T J McElwain; C L Harmer; K Atkinson; D E Austin
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

Review 4.  The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?

Authors:  Magdalena Witkowska; Agata Majchrzak; Piotr Smolewski
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.